000			03485nam a22004575i 4500
001			978-1-59745-274-8
003			DE-He213
005			20161121230803.0
007			cr nn 008mamaa
008			100301s2008 xxu| s |||| 0|eng d
020			_a9781597452748 _9978-1-59745-274-8
024	7		_a10.1007/978-1-59745-274-8 _2doi
050		4	_aRC261-271
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
082	0	4	_a614.5999 _223
245	1	0	_aCheckpoint Responses in Cancer Therapy _h[electronic resource] / _cedited by Wei Dai.
264		1	_aTotowa, NJ : _bHumana Press, _c2008.
300			_aXIV, 314 p. 33 illus., 3 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aCancer Drug Discovery and Development•
505	0		_aRB-Pathway -- Targeting the p53/MDM2 Pathway for Cancer Therapy -- DNA Topoisomerases as Targets for the Chemotherapeutic Treatment of Cancer -- Targeting ATM/ATR in the DNA Damage Checkpoint -- Compounds that Abrogate the G2 Checkpoint -- CDK Inhibitors as Anticancer Agents -- CHFR as a Potential Anticancer Target -- Antimicrotubule Agents -- Kinesin Motor Inhibitors as Effective Anticancer Drugs -- Targeting the Spindle Checkpoint in Cancer Chemotherapy -- Antiproliferation Inhibitors Targeting Aurora Kinases -- Plks as Novel Targets for Cancer Drug Design -- Do Histone Deacetylase Inhibitors Target Cell Cycle Checkpoints that Monitor Heterochromatin Structure?.
520			_aExtensive research has uncovered a set of molecular surveillance mechanisms – commonly called "checkpoints" – which tightly monitor cell-cycle processes. Today’s anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now promises to uncover a new generation of anticancer drugs with improved therapeutic indices based on their ability to target emerging checkpoint components. Checkpoint Responses in Cancer Therapy summarizes the advances made over the past 20 years, identifying components of cell-cycle checkpoints and their molecular regulation during checkpoint activation and validating the use of checkpoint proteins as targets for the development of anticancer drugs. This book’s distinguished panel of authors takes a close look at topics ranging from the major molecular players affecting DNA synthesis and the response to DNA damage to advances made in the identification of chemical compounds capable of inhibiting individual mitotic kinases. Illuminating and authoritative, Checkpoint Responses in Cancer Therapy offers a critical summary of findings for researchers in the pharmaceutical and biotechnology industries and a valuable resource for academic scientists in cancer research and the study of cell-cycle regulation, signal transduction and apoptosis.
650		0	_aMedicine.
650		0	_aCancer research.
650		0	_aPharmacology.
650	1	4	_aBiomedicine.
650	2	4	_aCancer Research.
650	2	4	_aPharmacology/Toxicology.
700	1		_aDai, Wei. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781588299307
830		0	_aCancer Drug Discovery and Development•
856	4	0	_uhttp://dx.doi.org/10.1007/978-1-59745-274-8
912			_aZDB-2-SBL
950			_aBiomedical and Life Sciences (Springer-11642)
999			_c503959 _d503959